Dr. Joseph Armine Scopelliti, MD Internal Medicine - Gastroenterology Medicare: Medicare Enrolled Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-5858 |
Dr. Kevin Vincent Carey, MD Internal Medicine - Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-5858 |
Dr. Ukorn Srivatana, MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-5858 |
Dr. Thomas J Mcdonald Jr., MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-5858 |
Dr. Michael J. Georgetson, MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-5858 |
Dr. Matthew James Lincoln, DO Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-887-2852 Fax: 570-887-2345 |
Aran W Laing, MD Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1 Guthrie Sq, Sayre, PA 18840 Phone: 570-888-5858 |
News Archive
Human papillomavirus (HPV) is one of the most common sexually transmitted infections and cases various cancers in women and men.
Today, Hospital Corporation of America, together with Mercy Hospital, announced they had entered into a letter of intent for the sale of the hospital to HCA. Mercy's board of directors voted to sell the facility to HCA, citing the company's presence in South Florida and consistent provision of quality care.
Psychiatrically ill and nicotine-dependent individuals consume approximately 70 percent of all cigarettes smoked in the United States, according to an article in the November issue of The Archives of General Psychiatry.
Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.
› Verified 2 days ago